Ultragenyx Pharmaceutical Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RARE Nasdaq 2836 www.ultragenyx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) - Oct 2nd, 2026 12:00 am
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results - Sep 22nd, 2026 1:09 pm
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target? - Sep 22nd, 2026 4:18 am
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI - Sep 19th, 2026 8:10 am
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy - Sep 18th, 2026 8:49 am
/C O R R E C T I O N -- Andelyn Biosciences/ - Sep 18th, 2026 7:00 am
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy - Sep 18th, 2026 6:16 am
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) - Sep 18th, 2026 5:30 am
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains? - Sep 18th, 2026 5:28 am
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug - Sep 18th, 2026 4:24 am
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells - Sep 17th, 2026 5:33 pm
RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy - Sep 17th, 2026 4:36 pm
Ultragenyx Stock Jumps on Landmark FDA Approval - Sep 17th, 2026 3:13 pm
How This Gene Therapy Name Partially Reversed Its Catastrophic 44% Dive - Sep 17th, 2026 2:50 pm
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) - Sep 17th, 2026 1:48 pm
RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares - Sep 16th, 2026 1:38 pm
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next - Sep 15th, 2026 7:51 pm
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan - Sep 4th, 2026 7:08 pm
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - Sep 4th, 2026 6:18 pm